Showing results (11-20 of 33) with videos related to

Sort By:
Pageof 4
Scientific Reports|March 22, 2019
A novel ex vivo tumor system identifies Src-mediated invasion and metastasis in mesenchymal tumor cells in non-small cell lung cancerAparna Padhye, Christin Ungewiss, Jared J Fradette, et al.
Molecular Cancer Research : MCR|May 31, 2023
ZEB1 Is Regulated by K811 Acetylation to Promote Stability, NuRD Complex Interactions, EMT, and NSCLC MetastasisMabel Perez-Oquendo, Roxsan Manshouri, Yanhua Tian, et al.
The Journal of Pharmacy and Pharmacology|January 18, 2011
The extent of the uptake of plasmid into the skin determines the immune responses induced by a DNA vaccine applied topically onto the skinZhen Yu, Woon-Gye Chung, Brian R Sloat, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|August 30, 2011
EGFR-targeted stearoyl gemcitabine nanoparticles show enhanced anti-tumor activityMichael A Sandoval, Brian R Sloat, Dharmika S P Lansakara-P, et al.
Neoplasia (New York, N.Y.)|January 26, 2016
Synthesis, Characterization, and In Vitro and In Vivo Evaluations of 4-(N)-Docosahexaenoyl 2', 2'-Difluorodeoxycytidine with Potent and Broad-Spectrum Antitumor ActivityYoussef W Naguib, Dharmika Lansakara-P, Laura M Lashinger, et al.
The Journal of Clinical Investigation|September 1, 2023
Autotaxin suppresses cytotoxic T cells via LPAR5 to promote anti-PD-1 resistance in non-small cell lung cancerJessica M Konen, B Leticia Rodriguez, Haoyi Wu, et al.
Cancers|April 17, 2019
Ntrk1 Promotes Resistance to PD-1 Checkpoint Blockade in Mesenchymal Kras/p53 Mutant Lung CancerJessica M Konen, B Leticia Rodriguez, Jared J Fradette, et al.
Science Advances|June 19, 2021
p53 loss activates prometastatic secretory vesicle biogenesis in the GolgiXiaochao Tan, Priyam Banerjee, Lei Shi, et al.
The Journal of Clinical Investigation|September 15, 2020
A protumorigenic secretory pathway activated by p53 deficiency in lung adenocarcinomaXiaochao Tan, Lei Shi, Priyam Banerjee, et al.
Nature Communications|May 11, 2021
Th17 cells contribute to combination MEK inhibitor and anti-PD-L1 therapy resistance in KRAS/p53 mutant lung cancersDavid H Peng, B Leticia Rodriguez, Lixia Diao, et al.
Pageof 4